Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$28.03
▼ $0.40 (-1.4%)
Market data updated: 09/21 05:37 PM
Fundamentals updated: 09/21/2026
News analyzed: 09/21/2026
Market Cap
$1.81B
Day Range
$27.75 - $28.80
52-Week Range
$20.32 - $40.22
Beta
—
Next Earnings
02.11.2026
Support
$27.24
Resistance
$33.94
STOK is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+22.4% (1Y)
Strengths: 7/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 404.5%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $19.35 vs. price $28.03 (-31.0%)
Fair Value
Signal tension
Growth scores strong (82/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
38
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
58
Value
38
Momentum
13
Risk
48
Sentiment
38
Fundamental
25
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage on Stoke Therapeutics focuses on positive clinical trial progress, financial updates, and favorable analyst coverage. The company reported that its Dravet syndrome trial for lead
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Stoke Therapeutics, Inc.. News trend score: 38. Reason: 7 of the last 20 articles are negative, versus 5 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
25
🎯 Conviction (vs. Emotion)
60
Psychology
43
Fundamentals
25
Technical
13
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Price (3M)
-10%
Market Narrative
42
Fundamental Reality
60
Narrative Gap
-18
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 94/100
🔴 Weakest match
Jesse Livermore — 15/100
🗣️ Why do they disagree?
Based on Peter Lynch's documented principles, the model estimates that STOK is a strong growth candidate, reflected by his high score of 93, while Benjamin Graham's defensive criteria rate it only 25, indicating it fails his safety bar. Based on Samuel Nelson's and Philip Fisher's documented principles, the model estimates favorable cycle positioning (score 81) and exceptional company quality (score 75), showing a more optimistic view than the value‑focused investors. Based on Howard Marks' and Morgan Housel's documented principles, the model estimates moderate risk and a holdable but not effortless case, with scores ranging from 34 to 45 and cautionary risk‑valuation flags. Based on the documented principles of trend‑followers and efficiency‑market advocates such as Jesse Livermore, Burton Malkiel & John Bogle, and Jack Schwager, the model estimates a negative trend, weak evidence versus an index, and no compelling setup, reflected in their low scores below 40.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 94
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 93
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 87
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 85
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 75
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 73
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 61
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 57
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 43
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 40
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 25
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 15
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a trading range, but the picture isn't yet clear enough on the likely direction.
Low confidence
$27.24
Range Bottom
$33.94
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-11.2%
Net Margin
-3.7%
EBITDA Margin
-11.2%
ROE
-2.0%
ROA
-1.6%
ROIC
—
EPS
-$0.12
Cash
$84.22M
Total Debt
—
Current Ratio
5.28
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$28.03
Estimated Fair Value (DCF)
$19.35
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-31.0%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $56.14M | $51.51M |
| 2 | 19.4% | $67.02M | $56.41M |
| 3 | 13.8% | $76.24M | $58.87M |
| 4 | 8.1% | $82.43M | $58.40M |
| 5 | 2.5% | $84.49M | $54.91M |
Base FCF (last actual year)
$44.91M
Terminal Value
$1.33B
Present Value of Terminal Value
$865.95M
Enterprise Value
$1.15B
Net Debt
$0
Equity Value
$1.15B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$5.95
Tangible Book Value per Share (Tangible NAV)
$5.95
Sentiment based on basic keywords (not AI) — 5 positive, 8 neutral, 7 negative out of the last 20 articles.
Yahoo · 16.9.2026
Benzinga · 4.9.2026
Yahoo · 3.9.2026
Business Wire · 3.9.2026
Yahoo · 2.9.2026
Business Wire · 2.9.2026
Yahoo · 1.9.2026
Business Wire · 1.9.2026
Benzinga · 1.9.2026
Benzinga · 21.8.2026
InvestorsHub · 21.8.2026
Business Wire · 18.8.2026
MarketBeat · 18.8.2026
Motley Fool · 11.8.2026
SeekingAlpha · 7.8.2026
Yahoo · 7.8.2026
Simply Wall St. · 7.8.2026
Yahoo · 5.8.2026
SeekingAlpha · 5.8.2026
Business Wire · 5.8.2026
Stoke Therapeutics, Inc. (STOK) currently has a StockIQ AI score of 38/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
STOK currently scores 38/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, STOK's estimated fair value is $19.35, which is 31.0% below the current price of $28.03. This is one valuation model among several signals in the fair-value category, not a price target.
STOK's technical score is 13/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 404.5%; Earnings per share (EPS) growth: 92.7%; Free cash flow growth: 151.6%.
Based on the real signals StockIQ computed: Estimated fair value: $19.35 vs. price $28.03 (-31.0%); Operating margin: -11.2% (negative); Net margin: -3.7% (negative).
StockIQ has no recorded dividend payment history for STOK.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 12 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Ticho Barry | Open Market Sale | 1.9.2026 | 1,600 | -1,600 | $31.06 |
| Ticho Barry | Open Market Sale | 1.9.2026 | 3,945 | -3,945 | $30.51 |
| Kaye Edward M. MD | Open Market Sale | 18.8.2026 | 637 | -637 | $32.47 |
| Ticho Barry | Open Market Sale | 18.8.2026 | 4,525 | -4,525 | $32.01 |
| Ticho Barry | Open Market Sale | 18.8.2026 | 242 | -242 | $32.47 |
| Kaye Edward M. MD | Open Market Sale | 18.8.2026 | 11,930 | -11,930 | $32.01 |
| Allan Jonathan | Open Market Sale | 18.8.2026 | 2,716 | -2,716 | $32.01 |
| Allan Jonathan | Open Market Sale | 18.8.2026 | 145 | -145 | $32.47 |
| Ticho Barry | Exercise of Derivative Securities | 14.8.2026 | 10,000 | -10,000 | — |
| Ticho Barry | Exercise of Derivative Securities | 14.8.2026 | 10,000 | +10,000 | — |
| Allan Jonathan | Exercise of Derivative Securities | 14.8.2026 | 6,000 | -6,000 | — |
| Allan Jonathan | Exercise of Derivative Securities | 14.8.2026 | 6,000 | +6,000 | — |
| Kaye Edward M. MD | Exercise of Derivative Securities | 14.8.2026 | 26,250 | +26,250 | — |
| Kaye Edward M. MD | Exercise of Derivative Securities | 14.8.2026 | 26,250 | -26,250 | — |
| Ticho Barry | Open Market Sale | 3.8.2026 | 5,907 | -5,907 | $28.95 |
| Ticho Barry | Open Market Sale | 3.8.2026 | 1,269 | -1,269 | $29.45 |
| Ticho Barry | Open Market Sale | 3.8.2026 | 21,691 | -5,907 | $28.95 |
| Ticho Barry | Open Market Sale | 3.8.2026 | 20,422 | -1,269 | $29.45 |
| Harrison Seth Loring | Gift | 16.7.2026 | 19,441 | +19,441 | — |
| Harrison Seth Loring | Gift | 16.7.2026 | 7,639 | +7,639 | — |
| Harrison Seth Loring | Gift | 16.7.2026 | 17,786 | -17,786 | — |
| Harrison Seth Loring | Gift | 16.7.2026 | 17,786 | +17,786 | — |
| Harrison Seth Loring | Gift | 16.7.2026 | 14,777 | +14,777 | — |
| Harrison Seth Loring | Gift | 16.7.2026 | 21,000 | -21,000 | — |
| Harrison Seth Loring | Gift | 16.7.2026 | 7,639 | -7,639 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
11,203,427 shares short as of 2026-08-31 · vs. 15,809,687 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
59.6% of trading volume this week was short selling, vs. 51.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology